Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panitumumab plus FOLFIRI in metastatic colorectal cancer with low-frequency RAS mutation
2018-002849-11Phase 2Terminated
- Sponsor
- Klinikum der Universität München, Ludwig-Maximilians-Universität München, represented by the managing medical director
- Start
- Dec 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of panitumumab in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC) (3 arms), sponsored by Klinikum der Universität München, Ludwig-Maximilians-Universität München, represented by the managing medical director. Primary endpoint: Objective response rate. Started Dec 2018; status: terminated.
02
Drugs
panitumumab
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2018-002849-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002849-11.